Category Archives: GSK

GSK reports promising early results in ovarian and womb cancer drug trial

Posted on by

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, seeks to speed up drug development at the group.

The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.

Continue reading...

UK must reform drug pricing to become life sciences superpower, says GSK boss

Posted on by

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

GSK’s outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a “life sciences superpower” unless it overhauls drug pricing.

As ministers draw up proposals to increase the amount the NHS spends on new medicines by up to 25%, Walmsley said she was “hopeful and ambitious” that the standoff with the pharma industry could be resolved.

Continue reading...

Shares in European drug companies hit four-month low as Trump tariffs loom

Posted on by

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

Shares in European pharmaceutical companies have sunk to a four-month low, after Donald Trump repeated his threats to introduce tariffs on drug imports “within the next week or so”.

Europe’s Stoxx Health Care index slid by 2.8% on Wednesday, falling to its lowest level since mid-April, shortly after the US president’s initial “liberation day” tariff announcements.

Continue reading...